SCHEDULE: Vanguard Reports 0% Stake in 10X Genomics Post-Realignment

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in 10X Genomics Inc. following an internal organizational realignment.

Summary

• The Vanguard Group filed Amendment No. 7 to its Schedule 13G for 10X Genomics Inc. (CUSIP 88025U109).
• The filing indicates that The Vanguard Group now beneficially owns 0.00 shares, representing 0% of 10X Genomics Inc. common stock.
• This change is a direct result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions, in accordance with SEC Release No. 34-39538.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for 10X Genomics, as it primarily reflects an internal administrative change in how The Vanguard Group reports its beneficial ownership, rather than a substantive change in investment position or outlook for the issuer.

Future Outlook

No forward-looking statements regarding 10X Genomics' performance, strategy, or financial outlook are provided in this administrative filing.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Ashley Grim, Head of Global Fund Administration, The Vanguard Group)

Industry Context

StockSavvy.ai notes that Schedule 13G filings are primarily administrative disclosures by institutional investors, indicating beneficial ownership changes. This particular amendment reflects an internal organizational restructuring within The Vanguard Group, rather well-established practice for large asset managers, rather than a change in investment thesis regarding 10X Genomics or a broader industry trend affecting the biotechnology sector.

Stakeholder Impact

• Shareholders: Minimal direct impact, as the change is administrative for Vanguard's reporting structure, not a divestment based on 10X Genomics' performance.
• Employees, Customers, Suppliers, Creditors: No direct impact mentioned or implied by this administrative filing.

Key Dates

Keywords

10X Genomics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Realignment